期刊文献+

PI3K/Akt信号通路在虾青素调节LX-2细胞活化中作用 被引量:2

Role of PI3K/Akt signaling pathway in moderating effect of astaxanthin on activation of LX-2 cells
原文传递
导出
摘要 目的探讨磷脂酰肌醇3-激酶/蛋白激酶B(PI3K/Akt)信号通路在虾青素调节人肝星状细胞(LX-2细胞)活化中的作用。方法实验设对照组、低、中、高剂量虾青素组(5、10、20μmol/L)、抑制剂组(25μmol/L LY294002)、抑制剂+虾青素组(25μmol/L LY294002+20μmol/L虾青素),作用48 h后检测LX-2细胞中α-平滑肌肌动蛋白(α-SMA)和Ⅰ型胶原(col1a1)mRNA表达水平、各组细胞Akt及其磷酸化水平。结果与对照组比较,虾青素组LX-2细胞中α-SMA和col1a1 mRNA表达明显降低,并呈剂量依赖关系(P<0.05);与对照组比较,抑制剂组LX-2细胞中磷酸化Akt水平(0.42±0.05)、α-SMA和col1a1 mRNA表达水平[分别为(0.23±0.05)、(0.35±0.06)]均明显降低(P<0.05);与对照组比较,虾青素组LX-2细胞中磷酸化Akt水平(0.60±0.07)、α-SM A和col1a1 mRNA表达水平[分别为(0.48±0.07)、(0.61±0.04)]均明显降低(P<0.05);与抑制剂组比较,抑制剂+虾青素组LX-2细胞中磷酸化Akt水平(0.18±0.04)、α-SMA和col1a1 mRNA表达水平[分别为(0.11±0.05)、(0.20±0.03)]均明显降低(P<0.05)。结论虾青素可通过PI3K/Akt信号通路抑制肝星状细胞活化,发挥抗非酒精性脂肪肝纤维化作用。 Objective To investigate the role of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signa- ling pathway in moderating effect of astaxanthin on the activation of human hepatic stellate cells ( LX-2 cell). Methods LX-2 cells were divided into a control group, three astaxanthin groups at the dosages of 5,10, and 20μmol/L, and in- hibitor group (25 μmol/L LY294002), and an inhibitor plus astaxanthin group (25μmol/L LY294002 and 20 μmol/L astaxanthin). The mRNA expressions of a-smooth muscle actin (α-SMA) and collagen I (coil al ), and protein expres- sion of Akt,phosphorylated Akt (p-Akt) in LX-2 cells were detected 48 hours after the treatments. Results The mRNA expressions of tx-SMA and collal in LX-2 cells of astaxanthin groups were obviously decreased in a dose-response manner compared with those of the control group (both P 〈 0. 05 ). The protein expression of p-Akt (0. 42 ±0.05 ) and mRNA expressions of α-SMA (0. 23 ±. 05) and collal (0. 35 ±. 06) in LX-2 cells of inhibitor group were obviously reduced compared to those of the control group ( all P 〈 0. 05 ) ; the protein expression of p-Akt ( 0. 60 ± 0.07 ) and mRNA expressions of α-SMA (0. 48 ±0. 07 )and coil al (0. 61 ±0. 04) in LX-2 cells of astaxanthin groups were obvi- ously decreased compared to those of the control group ( all P 〈 0. 05 ) ; the protein expression of p-Akt (0. 18 ±0. 04) and mRNA expressions of α-SMA (0. 11 ± 0. 05 ) and coil al (0. 20 ±0. 03 ) in LX-2 cells of inhibitor plus astaxanthin group were obviously reduced compared with those of the inhibitor group ( all P 〈 0. 05 ). Conclusion Astaxanthin can restrain the activation of hepatic stellate cells through the PI3K/Akt signaling pathway and play an important role in inhibiting the occurrence of fibrosis in non-alcoholic fatty liver disease.
出处 《中国公共卫生》 CAS CSCD 北大核心 2016年第11期1491-1494,共4页 Chinese Journal of Public Health
基金 国家自然科学基金(81302416) 广东省科技计划项目(2013B031800016 2014A020212297) 广东省高校优秀青年教师培养计划项目(YQ201405) 东莞市科技计划项目(2014108101053) 大学生创新创业训练计划项目(12205010022 201410571034 ZZDG015)
关键词 虾青素 肝星状细胞 肝纤维化 磷脂酰肌醇3-激酶/蛋白激酶B astaxanthin hepatic stellate cells hepatic fibrosis phosphatidylinositol 3-kinase/protein kinase B
  • 相关文献

参考文献1

二级参考文献16

  • 1Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholicfatty liver disease and steatohepatitis: Current status [J]. Advances in Therapy, 2009, 26 (10): 893-907.
  • 2Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease[J].TherapAdvGastroenterol, 2010, 3 (2): 121-137.
  • 3Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease [J]. The American journal of clinical nutrition, 2007, 86 (2) : 285-300.
  • 4Cortez-Pinto H, Jesus L, Barros H, et al. How different is the dietary pattern in non-alcoholic steatohepatitis patients? [J ]. Clinical nutrition (Edinburgh, Scotland), 2006, 25 (5): 816-823.
  • 5Sullivan S. Implications of diet on nonalcoholic fatty liver disease [J]. Current Opinion in Gastroenterology, 2010, 26 (2) : 160- 164.
  • 6Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis [J]. New England Journal of Medicine, 2010, 362 (18): 1675-1685.
  • 7Park JS, Chyun JH, Kim YK, et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans[J]. Nutrition & metabolism, 2010, 7: 18.
  • 8Fassett RG, Coombes JS. Astaxanthin: a potential therapeutic agent in cardiovascular disease [J]. Marine Drugs, 2011, 9 (3) : 447-465.
  • 9Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease inChina[J].JoumalofHepatology, 2009, 50 (1): 204- 210.
  • 10Ekstedt hi, Franz 6 n LE, Mathiesen UL, et al. Long-term follow- up of patients with NAFLD and elevated liver enzymes [J]. Hepatology (Baltimore, Md.), 2006, 44 (4): 865-873.

共引文献4

同被引文献19

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部